

# Angiotensin Converting Enzyme II

Subjects: Critical Care Medicine


Contributor: Reza Nejat, Maziar Fayaz Torshizi, David J. Najafi

Angiotensin converting enzyme II (ACE2), a type I transmembrane mono-carboxypeptidase of renin angiotensin system (RAS), is involved in conversion of angiotensin I (Ang I) and angiotensin II (Ang II) to angiotensin (1-9) and angiotensin (1-7), respectively. This enzyme, as the receptor of SARS-CoV-2, plays a crucial role in the virus entrance into the host cells. The docking of the S protein to this receptor, eventually leads to the fusion of the virus membrane with the host cell plasma membrane to release the viral genome into the cell cytoplasm.

Keywords: ACE2 ; Ang II ; angiotensin(1–7) ; AT1R ; SARS-CoV-2 ; ADAM17 ; soluble ACE2 ; MAPK ; PKC ; RBD ; ACE2 autoantibody

## 1. S Protein Structure

S protein of SARS-CoV-2 (of 1273 amino acid residues), a class I fusion and homo-trimeric glycoprotein, is composed of two subunits, S1 and S2, in each of its monomers. The former is in charge of docking of the virion to ACE2 and the latter promotes fusion of viral and host cell lipid outer membranes through a fusogenic process [1]. From N- toward C-terminal ends, S1 comprises a signaling sequence, an N-terminal domain (NTD), a receptor binding domain (RBD) including its receptor binding motif (RBM) and two subdomains (SD1 and SD2) [2][3]. S2, a rather conserved molecule in SARS-CoV and SARS-CoV-2, consists of a fusion peptide (FP), the heptad repeat 1 (HR1), the heptad repeat 2 (HR2), a transmembrane domain (TM) and a cytoplasmic tail (CT) [1][4]. Absent in SARS-CoV, a polybasic amino acid sequence, RRAR (Arg-Arg-Ala-Arg), called the furin-cleavage site is located at the S1/S2 boundary, the deletion of which attenuates SARS-CoV-2 replication in the respiratory cells [5] (**Figure 1**). It has been shown that the presence of the RRAR motif enables SARS-CoV-2 to evade endosomal interferon-induced transmembrane (IFITM) proteins [6].




**Figure 1.** S protein (monomer). PDB (RCSB.org) ID: 7QUS [7]. NTD: N-terminal Domain, RBD: Receptor Binding Domain


## 2. Binding of ACE2 with RBD Increases the Chance of Further Complexification of ACE2 and SARS-CoV-2

Binding of RBD with ACE2 is the first step of virus cell entry. Glycosylation of ACE2 and RBD residues may block this process [8]. However, RBDs in a trimeric S protein are not always accessible for this complexification and may be packed

together [9]. Constitutively, the RBD position within the S1 structure shifts dynamically through an intrinsic hinge-like movement between “open or up (U)” and “closed or down (D)” states [2]. RBD in U status moves outward the apex of S1 domain to be ACE2-accessible while in D position it hides within the protein apex to be ACE2-inaccessible [10] (**Figure 2** and **Figure 3**).



**Figure 2.** Two views of the trimeric SARS-CoV-2 S protein with the three RBDs in closed (DDD) state. PDB ID (RCSB.org): 7UB5 [11]. (A) Top apex view: the positions of RBDs (stars) show that these domains are hidden within the core of the molecule in the apex in DDD state. (B) Longitudinal lateral view: RBDs hidden position and NTD1 position in behind the molecule are pointed by the stars. All the arrows and the stars show the position of the domain territories. It is observable that the monomers of S protein are intertwined so that S1 in one monomer is in the proximity of S2 of the neighboring monomer (see the text). NTD: N-terminal domain; RBD: receptor binding domain



**Figure 3.** The trimeric form of SARS-CoV-2 S protein. RBD of the first monomer (RBD1) is attached to ACE2 catalytic domain. PDB ID (RCSB.org): 7VXA [12]. The intertwined positions of NTDs and RBDs of each monomer with the other monomers are noticeable. RBD of the second and third monomers (RBD2 and RBD3) are in open (U) and closed (D) states, respectively. NTD2 is identified by the yellow star pointed with the yellow arrow. Residue 614 is the point of


attachment of ACE2 catalytic domain with its “Neck” domain (see the text). ACE2: angiotensin converting enzyme 2; NTD: N-terminal domain; RBD: receptor binding domain.

As to the trimeric nature of S protein and considering U or D states of RBD, the apex of the trimeric S1 might harbor symmetric three open (UUU) or three closed (DDD) RBDs as well as intermediate asymmetric conformations of one open/two closed (UDD) or two open/one closed (UUD) ACE2-binding domains (**Figure 2** and **Figure 3**). The predominant RBD conformation (UUU, DDD or other intermediates) differs in the variants of the SARS-CoV-2 [13]. Recent studies attributed the escalated transmissibility and virulence of the new mutant variants to the abundance and stability of RBD in the U state [13][14]. Moreover, according to cryo-electron microscopy findings, docking of the single open RBD to ACE2 induces a rotation of the same domain which provokes its center of mass within the UDD complex to move approximately 5.5 Å away from the axis of the whole trimeric S protein molecule. This rotation is accompanied by moving of the three NTDs in the trimer of about 1.5–3.0 Å [15] which results in a reduction in the contact area among S1 subunits and the neighboring S2 core. This causes successive gaining of U state in the neighboring two D-positioned RBDs within the trimeric S protein [15]. To make it more clear, it should be noticed that in ACE2-unbound form of closed RBD, there are  $\pi$ - $\pi$  interactions among some residues of S1 in one protomer and Tyr(Y)837 of S2 in the neighboring protomer in addition to a salt bridge between Asp(D)614 of S1 and Lys(K)854 of the S2 which are disordered after ACE2 binding [15]. In D614G (Asp614 to Glycine) mutation, the hydrogen bond between D614 residue of SD2 (of S1 subunit in one protomer) and Threonine(T)859 residue of S2 subunit in the neighboring protomer is deleted which induces S1 to move away from S-trimer axis [2][16]. These conformational changes bringing about successive expression of more U states results in escalating the probability of complexification, not the affinity, of RBD with ACE2 [16]. Clarifying this issue needs to consider that the binding affinity (according to its definition [17]) depends on the quantity and type of the mutations crowded in RBD which determine the density and dynamicity of polar interactions of RBM interfacial and non-interfacial amino acid residues with the counterpart residues of ACE2 [18][19].


### 3. Membrane-Bound and Soluble ACE2

ACE2 contributes to infectivity and the entry of SARS-CoV-2 into the host cells while physiologically plays a crucial role in protection of the lungs, heart and other tissues against a variety of inflammatory or hypoxia-induced insults [20][21][22][23]. The non-homogenous distribution of ACE2, yet in a limited scale compared to ACE, was shown in a wide variety of tissues with the highest expression in the small intestine, heart, testis, thyroid glands and adipose tissue; intermediate expression in the lungs, colon, liver, bladder and adrenal glands; and the lowest content in the blood, spleen, bone marrow, brain, blood vessels and muscles [24]. Beyond the genetic traits determined by loci near immune related genes such as *IFNAR2* and *CXCR6* [25], the distinct genetic variants of highly polymorphic *Ace2* (gene located on chromosome Xp22.2 encoding for ACE2 protein [26]) in different populations have also been shown to affect the susceptibility to and severity of COVID-19 in some cohorts of patients [27][28][29][30].

ACE2, a type I transmembrane protein of 805 residues, comprises an extracellular segment (residues 19–740) including a signal peptide of 18 amino acids, an N-terminal claw-like protease domain (PD<sub>ACE2</sub>, residues 19–615) and a collectrin-like domain (residues 616–740) including ferredoxin-like fold “Neck” domain (residues 616–726) attached to a long transmembrane domain (residues 741–763) ending with a cytosolic C-terminal tail [31][32][33][34][35] (**Figure 4** and **Figure 5**). The cytosolic tail containing a conserved endocytosis short linear motif had been demonstrated to play a role in SARS-CoV-S protein-induced shedding of ACE2, TNF- $\alpha$  production and SARS-CoV infection [36][37] although a combined in silico and in vitro study strengthened by confocal imaging denied any role for C-terminal tail of ACE2 in SARS-CoV and SARS-CoV-2 cell entry [38]. The collectrin-like domain contributes to dimerization of two ACE2 molecules (assuming ACE2-A and ACE2-B) through interacting with Arg652, Glu653, Ser709, Arg710 and Asp713 in ACE2-A with Tyr641, Tyr633, Asn638, Glu639, Asn636 and Arg716 in ACE2-B [31].



**Figure 4.** Catalytic domain of ACE2 alone **(A)** and in binding with RBD of SARS-CoV-2 S protein **(B)**; PDB ID (RCSB.org): 6M0J [3]. ACE2: Angiotensin Converting Enzyme 2; RBD: receptor binding domain of SARS-CoV-2 S protein.



**Figure 5.** Full length of ACE2 molecule with the catalytic, the collectrin-like (Neck) and the trans-membrane domains; PDB ID (RCSB.org): 6M1D [39]. Residues 614-615 are the C-terminal amino acids of the catalytic domain of ACE2 which bind with the N-terminus of Neck domain of ACE2. ACE2: Angiotensin Converting Enzyme 2.

Physiologically, PD<sub>ACE2</sub> with its catalytic site removes one amino acid from the C-terminal end of angiotensin I (Ang I) and angiotensin II (Ang II) to turn them into angiotensin (1–9) and angiotensin (1–7), respectively [40]. An X-ray study uncovered the presence of a wide and deep cleft within the metallopeptidase catalytic domain of ACE2 with two subdomains I and II comprising its wall [41] (**Figure 4**). The catalytic efficiency of ACE2 for hydrolysis of Ang II is 400 times more than that of Ang I (as the precursor of Ang II) [40]. This means that any deficiency of ACE2 affects hydrolysis of Ang II 400 times more than that of its precursor, Ang I. Physiologically, this enzymatic hydrolysis leads to an increase in angiotensin(1–7)/Ang II concentration ratio resulting in attenuation of proinflammatory and organ-damaging effects of Ang II/AT1R pathway [42]. Conversely, deficiency of ACE2, which leads to an increase in tissue or plasma Ang II, may deprive the cell of one of its anti-inflammatory and protective tools [20]. An animal study on Ace2 (ACE2 gene) knockout mice proved that cardiac contractility is impaired, hypoxia-inducible genes such as BINP3 (encoding pro-apoptotic Bcl2 interacting protein) are upregulated and Ang II increases in the kidneys, heart and plasma [43][44]. Reciprocally, Ang II, while upregulates angiotensin converting enzyme (ACE), was shown, both in vitro and in vivo, to downregulate ACE2 expression at both mRNA and protein levels rather through a cellular inflammatory reaction induced by AT1R mediated



ERK/p38MAPK pathway [45][46]. Furthermore, as a positive feedback effect, Ang II through stimulation of AT1R promotes shedding of the membrane bound ACE2 (mACE2) ectodomain off the cell surface into the plasma as soluble ACE2 (sACE2; residues 18-708) [47] by inducing a sheddase protein, ADAM17 [48][49]. Both of these two effects, which results in a decrease in mACE2 and an increase in circulating sACE2, can be blocked by Ang II type I blockers (ARBs), e.g., losartan [45][46][49]. Consequently, the concentration of sACE2 increases in pathologies associated with higher AT1R stimulation such as myocardial infarction, heart failure, metabolic syndrome and diabetes mellitus [50][51][52].

## **4. ADAM17, the Sheddase of ACE2**

Regulated selective cleavage and release of the extracellular segment of many of transmembrane proteins into the extracellular space called “ectodomain shedding” modifies a diverse array of trans- and cis-signaling pathways [53]. ADAM17, the first identified shedding protease, is a Zn<sup>2+</sup>-dependent metalloproteinase and a member of the family of membrane-anchored ADAMs, which plays a role in both innate and humoral adaptive immunity, among the others [54]. This sheddase promotes proinflammatory effects through dissociating a variety of ligand proteins as its substrates including ACE2, TNF- $\alpha$  and transmembrane CX3CL as well as transmembrane receptors including IL6Ra and TNF receptors I and II [48][55][56][57][58]. Additionally, an animal study has revealed that ADAM17-induced degradation of interferon- $\gamma$  (IFN- $\gamma$ ) inhibits the latter’s anti-tumorigenic and anti-osteoclastogenic properties [59].

This metalloprotease exists in two forms: the full length pro-ADAM17 of 100KDa and the mature form of 80KDa lacking the inhibitory prodomain: the latter comprises almost two thirds of its total cell content which resides predominantly in perinuclear space along with TNF- $\alpha$  [60][61]. ADAM17 as a type I transmembrane multidomain proteinase comprises an N-terminal signal sequence, an inhibitory prodomain, a metalloproteinase catalytic domain, a disintegrin-like domain, a cysteine-rich and membrane proximal domains (MPD, involved in substrate recognition) attached to a single transmembrane domain (TMD) ending into a cytoplasmic tail [58][62]. The TMD, but not the cytoplasmic domain, contributes to the rapid activation of this metalloprotease by different signaling pathways [63]. However, phosphorylation of the cytoplasmic domain of ADAM17 by mitogen activating protein kinase (MAPK) network including p38MAPK and extracellular signal-regulated kinase (ERK) as well as Polo-like kinase2 (PLK2) keep this metalloprotease proteolytically functional through prevention of its dimerization and dampening of its binding to tissue inhibitor of metalloproteinase3 (TIMP3) at the cell surface [64][65]; TIMP3 plays an inhibitory role for the dimerized ADAM17 on the cell surface [66].

A proteolytically inactive rhomboid protein (iRhom2) encoded by *Rhbdf2* gene involved in innate immunity against viral infections [67], regulates trafficking of pro-ADAM17 from endoplasmic reticulum to Golgi apparatus where furin detaches ADAM17 inhibitory prodomain to make it mature, substrate specific and be prepared for expression on the cell surface in complex with iRhom2 [68][69]. Regulation of the function and substrate-selectivity of iRhom2/ADAM17 complex seem to be critically dependent on the interactions between TMDs and juxtamembrane domains (JMDs) of ADAM17 and iRhom2 [70]. Infection with DNA and RNA viruses (influenza A, RSV) upregulates *Rhbdf2* and *ADAM17* genes [69]. However, an in vivo study revealed that ADAM17-dependent ectodomain shedding is a saturable phenomenon: it does not increase significantly when ADAM17 expression rises above a certain level [71]. It must be mentioned that this metalloprotease is rapidly and reversibly switched “on” and “off” through conformational changes making its catalytic domain accessible and inaccessible, respectively, yet independent of removal of the inhibitory pro-domain or dissociation of TIMP3 [72].

Given that ADAM17 small interfering RNA (siRNA) is capable of attenuating Ang II-mediated inflammation in vascular smooth muscle cells [73] it is implied that along with other downstream mediators, ADAM17 is also involved in Ang II-induced inflammatory responses. Additionally, Ang II-mediated stimulation of AT1R, a G-protein coupled receptor (GPCR), provokes oxidative stress, induces phospholipase C (PLC)-mediated protein kinase C (PKC) activation and increases calcium influx [74][75][76][77]. Oxidative stress in tumor cells and platelets could previously be found to activate ADAM17 with pro-inflammatory effects (see previous paragraph) [78][79]. Reciprocally, ADAM17 in a mouse model could also increase NADPH oxidase 4 (Nox4) activity resulting in oxidative stress [80] which by inducing pro-inflammatory genes is intertwined with inflammation [81][82]. It is, however, noticeable that ADAM17 positively regulates Thioredoxin-1 (Trx-1) activity as the key effector of intracellular reducing system and downregulates ADAM17 as a negative feedback effect [83][84].

Furthermore, the PKC pathway, depending on the nature of its activator, affects ADAM17-dependent ectodomain shedding. Short-term (minutes) activation of protein kinase C (PKC) by phorbol ester (the strongest non-physiologic stimulator of PKC) increases ADAM17 content on the cell plasma membrane and the sheddase activity while prolonged (hours) exposure to phorbol ester downregulates mature form of ADAM17 on the cell surface abolishing the ectodomain shedding without reducing the total cell content of ADAM17 (mature plus pro-ADAM17) [85]. Conversely, ligand-activated GPCRs, such as thrombin-mediated protease activated receptor1 (PAR1), with the potential to activating of PKC signaling [86][87], induces sheddase function without any change in the content of ADAM17 on the plasma membrane [85]. Moreover,

Ang II, via AT1R, was found to upregulate PAR1 and PAR2 in rat aorta which lead to pro-inflammatory responses accompanied by raising IL-6 and monocyte chemoattractant protein-1 (MCP-1), the substrates of ADAM17 [61][88][89]. Along with the natural homo- and hetero-merization of GPCRs [75], an in vitro study revealed synergistic interaction between AT1R and PAR1 [90], implicating a positive influence of these receptors in activating ADAM17. Moreover, AT1R stimulation alone is associated with a rise in IL-1 $\beta$  which by itself promotes ectodomain shedding by ADAM17 [91][92]. Considering that Ang II via AT1R could induce PKC $\delta$ /p38MAPK [93] which also activates ADAM17 [94][95], it is logically implied that AT1R also potentiates ADAM17-induced ectodomain shedding through p38MAPK pathway. Ca<sup>2+</sup> influx and calmodulin inhibition stimulate ADAM10 [96]. Given that ADAM17 is involved in processing of pro- $\alpha$ 2 $\delta$ -1 and  $\alpha$ 2 $\delta$ -3 subunits of voltage gated calcium channels which enhances calcium influx [97] it is implied that ADAM17 also indirectly contributes to activating ADAM10 in ectodomain shedding.

## **5. Shedding of ACE2 Ectodomain and sACE2 in SARS-CoV-2**

As was mentioned previously, ADAM10 and ADAM17, the predominant sheddases, contribute to cleaving mACE2 off the cell surface which lead to a vast array of physiological and pathological cis- and trans-signaling [55]. Cleavage of the ectodomain of mACE2 occurs through a basal low level constitutive or a metalloproteinase-dependent fashion [98]. A cell culture study showed that inhibition of both ADAM17 and ADAM10, widely found on pneumocyte type I and II, results in ACE2 increment on the surface of these cells [99]. Consistently, an animal model of diabetes proved that ADAM17 gene knockdown and overexpression could reduce and raise mACE2 shedding off the cardiomyocytes, respectively [100].

Oxidative stress, MAPK network, PKC and Ca<sup>2+</sup> signaling activation in various viral infections including SARS-CoV and SARS-CoV-2 has already been described [101][102][103][104][105][106][107][108]. Ang II-mediated AT1R stimulation activates these signaling pathways, as well [109][110]. All these signaling pathways directly promote ADAM17-dependent ACE2 shedding which by itself decreases angiotensin(1–7)/Ang II concentration ratio and promotes Ang II/AT1R pathway which also induces ADAM17 sheddase function (see previous section). Additionally, COVID-19 has been shown to promote ADAM17 expression both at the protein and transcriptional level [111].

In this context, neither should it be forgotten that the downregulation of mACE2 in COVID19 can be due to internalization of the virus-ACE2 complex [112][113][114][115] nor should the cleaving effects of TMPRSS2 along with ADAM17 be ignored. These two proteases compete in shedding, yet at different sites, of ACE2: ADAM17 and TMPRSS2 cleave Arginine and Lysine amino acids in residues 652–659 and 697–716, respectively [116]. However, TMPRSS2-mediated dissociation of mACE2 does not result in the release of sACE2 [117].

It was also shown that docking of the SARS-CoV S protein with ACE2 could induce detachment of the latter off the cell membrane by ADAM17, which can be blocked by the TNF protease inhibitor 2 (TAPI-2) [36]. Concordantly, SARS-CoV infection was shown to downregulate mACE2 in Vero E6 and the cells of the lungs in mice [118][119]. Anti-ADAM17 compounds after SARS-CoV infection could, in vitro and in vivo, inhibit ACE2 shedding, reduce sACE2 and suppress infectivity of the virus [120]. Consistently, a cell culture study confirmed that SARS-CoV-2 S protein induces metalloproteinase-dependent ACE2 shedding [121]. Kornilov et al., in the early months after the COVID-19 pandemic, considered the elevated plasma level of sACE2 as a biomarker or possible cause of more severe SARS-CoV-2 infection seen in pathologies associated with higher levels of sACE2, e.g., diabetes, heart failure, metabolic syndrome and myocardial infarction as well as in the old, men and postmenopausal women [122]. Concordantly, in a study on 42 hospitalized patients with moderate to severe SARS-CoV-2 infection, sACE2 level was higher in all patients compared to healthy control group on the day of admission (DOA) which even rose in a meaningful manner within the next 7 days of hospitalization. During this period, the upward slope of sACE2 level was even significantly steeper in severe vs moderate cases and the escalating trend continued in male sharper than that of female patients and in all hypertensive as well as diabetic COVID-19 cases under study. The strong positive correlation of the raised sACE2 with D-dimer levels in this study implies that sACE2 may contribute to hypercoagulability state seen in SARS-CoV-2 infection albeit it needs to be studied more [123].

Whatever the mechanism is, cleavage of mACE2 reduces its presence on the cell membrane and raises its soluble form (sACE2, containing PD<sub>ACE2</sub> including RBD docking domain) in extracellular space including airway surface liquid covering the lung epithelial cells [124][125]. Furthermore, a recent prospective study on 119 SARS-CoV-2 infected patients compared to 23 adult non-COVID controls revealed that autoantibodies against ACE2 (AA-ACE2; with antagonistic effect against mACE2) and AT1R (AA-AT1R; with agonistic effect on the receptor) developed in COVID patients. Intriguingly a more rise in AA-ACE2 and AA-AT1R levels was observed in the moderate and severe groups than in the mild group. The presence of AA-ACE2 was postulated to have originated from immunologic reaction against SARS-CoV-2-sACE2 complex; the

autoantibodies are likely anti-idiotypic antibodies against antigen binding sites of the antibodies developed against RBD of SARS-CoV-2 [126][127]. In addition, the activity of plasma sACE2 decreased in the presence of AA-ACE2 [127].

---

## References

1. Wang M-Y, Zhao R, Gao L-J, Gao X-F, Wang D-P, Cao J-M; SARS-CoV-2: structure, biology, and structure-based therapeutics development.. *Frontiers in cellular and infection microbiology* **2020**, 10, 587269, .
2. Berger I, Schaffitzel C; The SARS-CoV-2 spike protein: balancing stability and infectivity. *Cell research* **2020**, 30 (12), 1059-1060, .
3. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L.; Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* **2020**, 581(7807), 215-220, .
4. Shah P, Canziani GA, Carter EP, Chaiken I; The case for S2: the potential benefits of the S2 subunit of the SARS-CoV-2 spike protein as an immunogen in fighting the COVID-19 pandemic. *Frontiers in immunology* **2021**, 12, 637651, .
5. Wu Y, Zhao S; Furin cleavage sites naturally occur in coronaviruses. *Stem cell research* **2021**, 50, 102115, .
6. Peacock TP, Goldhill DH, Zhou J, Baillon L, Frise R, Swann OC, Kugathasan R, Penn R, Brown JC, Sanchez-David R Y.; The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets.. *Nature microbiology* **2021**, 6(7), 899-909, .
7. Buchanan CJ, Gaunt B, Harrison PJ, Yang Y, Liu, J.; Khan, A.; Giltrap, A.M.; Le Bas, A.; Ward, P.N.; Gupta, K.; Pathogen-sugar interactions revealed by universal saturation transfer analysis. *Science* **2022**, 377, eabm3125, .
8. Mehdi-pour AR, Hummer G.; Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. *Proceedings of the National Academy of Sciences* **2021**, 118(19), e2100425118, .
9. Zhu C, He G, Yin Q, Zeng L, Ye X, Shi Y, Xu W.; Molecular biology of the SARS-CoV-2 spike protein: A review of current knowledge. *Journal of Medical Virology* **2021**, 93(10), 5729-5741, .
10. Khare S, Azevedo M, Parajuli P, Gokulan K.; Conformational changes of the receptor binding domain of sars-cov-2 spike protein and prediction of a b-cell antigenic epitope using structural data. *Frontiers in Artificial Intelligence* **2021**, 4, 31, .
11. Stalls V, Lindenberger J, Gobeil SM-C, Henderson R, Parks R, Barr M, Deyton M, Martin M, Janowska K, Huang X.; Cryo-EM structures of SARS-CoV-2 Omicron BA. 2 spike. *Cell Reports* **2022**, 39(13), 111009, .
12. Wang Y, Xu C, Wang Y, Hong Q, Zhang C, Li Z, Xu S, Zuo Q, Liu C, Huang Z.; Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM. *Nature communications* **2021**, 12(1), 7345, .
13. Yurkovetskiy L, Wang X, Pascal KE, Tomkins-Tinch C, Nyalile TP, Wang Y, Baum A, Diehl WE, Dauphin A, Carbone C.; Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. *Cell* **2020**, 183(3), 739-751. e738, .
14. Giron CC, Laaksonen A, Barroso da Silva FL.; Up state of the SARS-COV-2 spike homotrimer favors an increased virulence for new variants. *Frontiers in medical technology* **2021**, 3, 694347, .
15. Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ.; Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. *Nature* **2020**, 588(7837), 327-330, .
16. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B.; Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell* **2020**, 182(4), 812-827. e819, .
17. Jordan M.; The meaning of affinity and the importance of identity in the designed world. *Interactions* **2010**, 17(5), 6-11, .
18. Delgado JM, Duro N, Rogers DM, Tkatchenko A, Pandit SA, Varma S.; Molecular basis for higher affinity of SARS-CoV-2 spike RBD for human ACE2 receptor. *Proteins: Structure, Function, and Bioinformatics* **2021**, 89(9), 1134-1144, .
19. Wu L, Zhou L, Mo M, Liu T, Wu C, Gong C, Lu K, Gong L, Zhu W, Xu Z.; SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2. *Signal transduction and targeted therapy* **2022**, 7(1), 1-3, .
20. Turner, A.; . The Protective Arm of the Renin Angiotensin System (RAS): Functional Aspects and Therapeutic Implications; Unger, T., Steckelings, U.M., Eds.; Academic Press:: London, UK, 2015; pp. 185-189.
21. Scialo F, Daniele A, Amato F, Pastore L, Matera MG, Cazzola M, Castaldo G, Bianco A.; ACE2: the major cell entry receptor for SARS-CoV-2. *Lung* **2020**, 198(6), 867-877, .

22. Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM.; Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SAR S receptor, and a partner for amino acid transporters. *Pharmacology & therapeutics* **2010**, 128(1), 119-128, .
23. Hu H, Zhang R, Dong L, Chen E, Ying K.; Overexpression of ACE2 prevents hypoxia-induced pulmonary hypertension in rats by inhibiting proliferation and immigration of PSMCs. *Eur Rev Med Pharmacol Sci* **2020**, 24(7), 3968-3980, .
24. Li M-Y, Li L, Zhang Y, Wang X-S.; Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infectious diseases of poverty* **2020**, 9, 23-29, .
25. Neimi, M.E.K.; Karjalainen, J.; Liao, R.G.; Neale, B.M.; Daly, M.; Ganna, A.; Pathak, G.A.; Andrews, S.J.; Kanai, M.; Verapen, K.; et al. Mapping the human genetic architecture of COVID-19. *Nature* **2021**, 600, 472-477, .
26. Luo Y, Liu C, Guan T, Li Y, Lai Y, Li F, Zhao H, Maimaiti T, Zeyaweidong A.; Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang. *Hypertension Research* **2019**, 42(5), 681-689, .
27. Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, Wen F, Huang X, Ning G, Wang W: in different populations. *Cell discovery* 2020, 6(1):1-4; Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. *Cell discovery* **2020**, 6(1), 1-4, .
28. Lanjanian H, Moazzam-Jazi M, Hedayati M, Akbarzadeh M, Guity K, Sedaghati-Khayat B, Azizi F, Daneshpour MS.; SARS-CoV-2 infection susceptibility influenced by ACE2 genetic polymorphisms: insights from Tehran Cardio-Metabolic Genetic Study. *Scientific reports* **2021**, 11(1), 1-13, .
29. Li J, Wang Y, Liu Y, Zhang Z, Zhai Y, Dai Y, Wu Z, Nie X, Du L.; Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review. *European Journal of Medical Research* **2022**, 27(1), 1-10, .
30. Singh H, Choudhari R, Nema V, Khan AA.; ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease. *Microbial pathogenesis* **2021**, 150, 104621, .
31. Senapati S, Banerjee P, Bhagavatula S, Kushwaha PP, Kumar S.; Contributions of human ACE2 and TMPRSS2 in determining host–pathogen interaction of COVID-19. *Journal of Genetics* **2021**, 100(1), 1-16, .
32. Devaux CA, Rolain J-M, Raoult D.; ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. *Journal of Microbiology, Immunology and Infection* **2020**, 53(3), 425-435, .
33. Badawi S, Ali BR: ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis.; the saga continues. Badawi S, Ali BR: ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: the saga continues. *Human genomics* **2021**, 15(1), 1-14, .
34. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J-C, Turner AJ, Raizada MK, Grant MB, Oudit GY.; Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. *Circulation research* **2020**, 126(10), 1456-1474, .
35. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R.; A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circulation research* **2000**, 87(5), e1-e9, .
36. Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, Yamamoto N, Sasazuki T, Ishizaka Y.; Modulation of TNF- $\alpha$ -converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF- $\alpha$  production and facilitates viral entry. *Proceedings of the National Academy of Sciences* **2008**, 105(22), 7809-7814, .
37. Kliche J, Kuss H, Ali M, Ivarsson Y.; Cytoplasmic short linear motifs in ACE2 and integrin  $\beta$ 3 link SARS-CoV-2 host cell receptors to mediators of endocytosis and autophagy. *Science signaling* **2021**, 14(665), eabf1117, .
38. Karthika T, Joseph J, Das V, Nair N, Charulekha P, Roji MD, Raj VS.; SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling. *Cells* **2021**, 10(7), 1814, .
39. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q.; Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* **2020**, 367(6485), 1444-1448, .
40. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F.; Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *Journal of Biological Chemistry* **2002**, 277(17), 14838-14843, .
41. Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, Ryan D, Fisher M, Williams D, Dales NA.; ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. *Journal of Biological Chemistry* **2004**, 279(17), 17996-18007, .
42. Villalobos LA, Hipólito-Luengo S, Ramos-González M, Cercas E, Vallejo S, Romero A, Romacho T, Carraro R, Sánchez-Ferrer CF, Peiró C.; The angiotensin-(1-7)/mas axis counteracts angiotensin II-dependent and-independent pro-inflammatory signaling in human vascular smooth muscle cells. *Frontiers in Pharmacology* **2016**, 7, 482, .



43. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y; Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature* **2002**, 417(6891), 822-828, .
44. Zhang J, Ney PA; Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. *Cell Death & Differentiation* **2009**, 16(7), 939-946, .
45. Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY; Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. *The American journal of pathology* **2008**, 172(5), 1174-1183, .
46. Gallagher PE, Ferrario CM, Tallant EA; MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. *American Journal of Physiology-Cell Physiology* **2008**, 295(5), C1169-C1174, .
47. Kumar SA, Wei H; Comparative docking studies to understand the binding affinity of nicotine with soluble ACE2 (sACE2)-SARS-CoV-2 complex over sACE2. *Toxicology reports* **2020**, 7, 1366-1372, .
48. Eguchi S, Kawai T, Scalia R, Rizzo V; Understanding angiotensin II type 1 receptor signaling in vascular pathophysiology. *Hypertension* **2018**, 71(5), 804-810, .
49. Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, Putko B, Kassiri Z, Turner AJ, Oudit GY; Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAAS. *Journal of molecular and cellular cardiology* **2014**, 66, 167-176, .
50. Ortiz-Pérez JT, Riera M, Bosch X, De Caralt TM, Perea RJ, Pascual J, Soler MJ; Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. *PLoS One* **2013**, 8(4), e61695, .
51. Ferder L, Inserra F, Martínez-Maldonado M; Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. *Current hypertension reports* **2006**, 8(3), 191-198, .
52. Chu KY, Leung PS; Angiotensin II in type 2 diabetes mellitus. *Current Protein and Peptide Science* **2009**, 10(1), 75-84, .
53. Hayashida K, Bartlett AH, Chen Y, Park PW; Molecular and cellular mechanisms of ectodomain shedding. *The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology* **2010**, 293(6), 925-937, .
54. Marczyńska J, Ozga A, Włodarczyk A, Majchrzak-Gorecka M, Kulig P, Banas M, Michalczyk-Wetula D, Majewski P, Hutloff A, Schwarz J; The role of metalloproteinase ADAM17 in regulating ICOS Ligand-mediated humoral immune responses. *The Journal of Immunology* **2014**, 193(6), 2753-2763, .
55. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A; The role of ADAM-mediated shedding in vascular biology. *European journal of cell biology* **2012**, 91(6-7), 472-485, .
56. Grötzinger J, Lorenzen I, Düsterhöft S; Molecular insights into the multilayered regulation of ADAM17: The role of the extracellular region. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research* **2017**, 1864(11), 2088-2095, .
57. Scheller J, Chalaris A, Garbers C, Rose-John S; ADAM17; a molecular switch to control inflammation and tissue regeneration. *Trends in immunology* **2011**, 32(8), 380-387, .
58. Zunke F, Rose-John S; The shedding protease ADAM17: Physiology and pathophysiology. *BBA - Molecular Cell Research* **2017**, 1864, 2059-2070, .
59. Kanzaki H, Shinohara F, Suzuki M, Wada S, Miyamoto Y, Yamaguchi Y, Katsumata Y, Makihira S, Kawai T, Taubman MA; A-Disintegrin and metalloproteinase (ADAM) 17 enzymatically degrades interferon-gamma. *Scientific reports* **2016**, 6(1), 32259, .
60. SCHLÖNDORFF J, BECHERER JD, BLOBEL CP; Intracellular maturation and localization of the tumour necrosis factor  $\alpha$  convertase (TACE). *Biochemical Journal* **2000**, 347(1), 131-138, .
61. De Queiroz TM, Lakkappa N, Lazartigues E; ADAM17-mediated shedding of inflammatory cytokines in hypertension. *Frontiers in Pharmacology* **2020**, 11, 1154, .
62. Lorenzen I, Lokau J, Düsterhöft S, Trad A, Garbers C, Scheller J, Rose-John S, Grötzinger J; The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. *FEBS letters* **2012**, 586(8), 1093-1100, .
63. Weskamp G, Tüshaus J, Li D, Feederle R, Maretzky T, Swendemann S, Falck-Pedersen E, McIlwain DR, Mak TW, Salmon JE; ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1). *Journal of Biological Chemistry* **2020**, 295(13), 4350-4358, .
64. Al-Salihi MA, Lang PA; iRhom2; an emerging adaptor regulating immunity and disease. *International Journal of Molecular Sciences* **2020**, 21(18), 6570, .

65. Saad MI, Alhayyani S, McLeod L, Yu L, Alanazi M, Deswaerte V, Tang K, Jarde T, Smith JA, Prodanovic Z.; ADAM 17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer. *EMBO molecular medicine* **2019**, *11*(4), e9976, .
66. Fan D, Kassiri Z.; Biology of tissue inhibitor of metalloproteinase 3 (TIMP3), and its therapeutic implications in cardiovascular pathology. *Frontiers in Physiology* **2020**, *11*, 661, .
67. Luo W-W, Li S, Li C, Zheng Z-Q, Cao P, Tong Z, Lian H, Wang S-Y, Shu H-B, Wang Y-Y.; iRhom2 is essential for innate immunity to RNA virus by antagonizing ER-and mitochondria-associated degradation of VISA. *PLoS pathogens* **2017**, *13*(11), e1006693, .
68. Adrain C, Zettl M, Christova Y, Taylor N, Freeman M.; Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. *Science* **2012**, *335*(6065), 225-228, .
69. Chao-Chu J, Murtough S, Zaman N, Pennington DJ, Blaydon DC, Kelsell DP.; iRHOM2: A Regulator of Palmoplantar Biology, Inflammation, and Viral Susceptibility. *Journal of Investigative Dermatology* **2021**, *141*(4), 722-726, .
70. Substrate-selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains. *FASEB journal*; Tang B, Li X, Maretzky T, Perez-Aguilar JM, McIlwain D, Xie Y, Zheng Y, Mak TW, Weinstein H, Blobel CP. *Faseb Journal: official publication of the Federation of American Societies for Experimental Biology* **2020**, *34*(4), 4956, .
71. Yoda M, Kimura T, Tohmonda T, Morioka H, Matsumoto M, Okada Y, Toyama Y, Horiuchi K.; Systemic overexpression of TNF $\alpha$ -converting enzyme does not lead to enhanced shedding activity in vivo. *PloS one* **2013**, *8*(1), e54412, .
72. Le Gall SM, Maretzky T, Issuree PD, Niu X-D, Reiss K, Saftig P, Khokha R, Lundell D, Blobel CP.; ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. *Journal of cell science* **2010**, *123*(22), 3913-3922, .
73. Zeng S-y, Yang L, Hong C-l, Lu H-q, Yan Q-j, Chen Y, Qin X-p.; Evidence That ADAM17 Mediates the Protective Action of CGRP against Angiotensin II-Induced Inflammation in Vascular Smooth Muscle Cells. *Mediators of Inflammation* **2018**, *2018*, 2109352, .
74. Guo DF, Sun YL, Hamet P, Inagami T.; The angiotensin II type 1 receptor and receptor-associated proteins. *Cell research* **2001**, *11*(3), 165-180, .
75. Nejat R, Sadr AS, Torshizi MF, Najafi DJ.; GPCRs of Diverse Physiologic and Pathologic Effects with Fingerprints in COVID-19. *Biology and Life Sciences Forum* **2021**, *7*(1), 19, .
76. Fuller AJ, Hauschild BC, Gonzalez-Villalobos R, Awayda MS, Imig JD, Inscho EW, Navar LG.; Calcium and chloride channel activation by angiotensin II-AT1 receptors in preglomerular vascular smooth muscle cells. *American Journal of Physiology-Renal Physiology* **2005**, *289*(4), F760-F767, .
77. Vivar R, Soto C, Copaja M, Mateluna F, Aranguiz P, Munoz JP, Chiong M, Garcia L, Letelier A, Thomas WG.; Phospholipase C/protein kinase C pathway mediates angiotensin II-dependent apoptosis in neonatal rat cardiac fibroblasts expressing AT1 receptor. *Journal of cardiovascular pharmacology* **2008**, *52*(2), 184-190, .
78. Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A.; Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. *Molecular and cellular biology* **2004**, *24*(12), 5172-5183, .
79. Brill A, Chauhan AK, Canault M, Walsh MT, Bergmeier W, Wagner DD.; Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion. *Cardiovascular research* **2009**, *84*(1), 137-144, .
80. Ford BM, Eid AA, Göőz M, Barnes JL, Gorin YC, Abboud HE.; ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice. *American Journal of Physiology-Renal Physiology* **2013**, *305*(3), F323-F332, .
81. Chatterjee, S. Oxidative stress and biomaterials; Dziubla, T; Butterfield, D.Allan, Eds.; Academic Press: Amsterdam, 2016; pp. 35-58.
82. Forcados GE, Muhammad A, Oladipo OO, Makama S, Meseko CA.; Metabolic implications of oxidative stress and inflammatory process in SARS-CoV-2 pathogenesis: therapeutic potential of natural antioxidants. *Frontiers in cellular and infection microbiology* **2021**, *11*, 654813, .
83. e Costa RA, Granato DC, Trino LD, Yokoo S, Carnielli CM, Kawahara R, Domingues RR, Pauletti BA, Neves LX, Santana AG.; ADAM17 cytoplasmic domain modulates Thioredoxin-1 conformation and activity. *Redox biology* **2020**, *37*, 101735, .
84. Granato DC, e Costa RA, Kawahara R, Yokoo S, Aragao AZ, Domingues RR, Pauletti BA, Honorato RV, Fattori J, Figueira ACM.; Thioredoxin-1 negatively modulates ADAM17 activity through direct binding and indirect reductive activity. *A*

85. Lorenzen I, Lokau J, Korpys Y, Oldefest M, Flynn CM, Künzel U, Garbers C, Freeman M, Grötzinger J, Düsterhöft S; C control of ADAM17 activity by regulation of its cellular localisation. *Scientific reports* **2016**, 6(1), 1-15, .
86. Fang Q, Liu X, Abe S, Kobayashi T, Wang X, Kohyama T, Hashimoto M, Wyatt T, Rennard S; Fang, Q; Liu, X; Abe, S; Kobayashi, T; Wang, X; Kohyama, T; Hashimoto, M; Wyatt, T; Rennard, S; Thrombin induces collagen gel contraction partially through PAR1 activation and PKC- $\epsilon$ . *European Respiratory Journal* **2004**, 24(6), 918-924, .
87. Yang C-C, Hsiao L-D, Shih Y-F, Hsu C-K, Hu C-Y, Yang C-M; Thrombin Induces COX-2 and PGE2 Expression via PAR1/PKC $\alpha$ /MAPK-Dependent NF- $\kappa$ B Activation in Human Tracheal Smooth Muscle Cells. *Mediators of Inflammation* **2022**, 2022, 4600029, .
88. He R-Q, Tang X-F, Zhang B-L, Li X-D, Hong M-N, Chen Q-Z, Han W-Q, Gao P-J; Protease-activated receptor 1 and 2 contribute to angiotensin II-induced activation of adventitial fibroblasts from rat aorta. *Biochemical and Biophysical Research Communications* **2016**, 473(2), 517-523, .
89. Menghini R, Fiorentino L, Casagrande V, Lauro R, Federici M; The role of ADAM17 in metabolic inflammation. *Atherosclerosis* **2013**, 228(1), 12-17, .
90. Zamel IA, Palakkott A, Ashraf A, Iratni R, Ayoub MA; Interplay between angiotensin II type 1 receptor and thrombin receptor revealed by bioluminescence resonance energy transfer assay. *Frontiers in Pharmacology* **2020**, 11, 1283, .
91. Hall KC, Blobel CP; Interleukin-1 stimulates ADAM17 through a mechanism independent of its cytoplasmic domain or phosphorylation at threonine 735. *PloS one* **2012**, 7(2), e31600, .
92. Pearl MH, Grotts J, Rossetti M, Zhang Q, Gjertson DW, Weng P, Elashoff D, Reed EF, Chambers ET; Cytokine profiles associated with angiotensin II type 1 receptor antibodies. *Kidney international reports* **2019**, 4(4), 541-550, .
93. Cardoso VG, Gonçalves GL, Costa-Pessoa JM, Thieme K, Lins BB, Casare FAM, de Ponte MC, Camara NOS, Oliveira-Souza M; Angiotensin II-induced podocyte apoptosis is mediated by endoplasmic reticulum stress/PKC- $\delta$ /p38 MAPK pathway activation and through increased Na<sup>+</sup>/H<sup>+</sup> exchanger isoform 1 activity. *BMC nephrology* **2018**, 19(1), 1-12, .
94. Zhu G, Liu J, Wang Y, Jia N, Wang W, Zhang J, Liang Y, Tian H, Zhang J; ADAM17 Mediates Hypoxia-Induced Keratinocyte Migration via the p38/MAPK Pathway. *BioMed research international* **2021**, 2021, 8328216, .
95. Xu P, Derynck R; Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. *Molecular cell* **2010**, 37(4), 551-566, .
96. Horiuchi K, Le Gall S, Schulte M, Yamaguchi T, Reiss K, Murphy G, Toyama Y, Hartmann D, Saftig P, Blobel CP; Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. *Molecular biology of the cell* **2007**, 18(1), 176-188, .
97. Kadurin I, Dahimene S, Page KM, Ellaway JI, Chaggar K, Troeberg L, Nagase H, Dolphin AC; ADAM17 mediates proteolytic maturation of voltage-gated calcium channel auxiliary  $\alpha 2\delta$  subunits, and enables calcium current enhancement. *Function* **2022**, 3(3), zqac013, .
98. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ; Tumor necrosis factor- $\alpha$  convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). *Journal of Biological Chemistry* **2005**, 280(34), 30113-30119, .
99. Jocher G, Grass V, Tschirner SK, Riepler L, Breimann S, Kaya T, Oelsner M, Hamad MS, Hofmann LI, Blobel CP; ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion. *EMBO reports* **2022**, 23(6), e54305, .
100. Cheng J, Xue F, Cheng C, Sui W, Zhang M, Qiao L, Ma J, Ji X, Chen W, Yu X; ADAM17 knockdown mitigates while ADAM17 overexpression aggravates cardiac fibrosis and dysfunction via regulating ACE2 shedding and myofibroblast transformation. *Frontiers in pharmacology* **2022**, 13, 997916, .
101. Kumar R, Khandelwal N, Thachamvally R, Tripathi BN, Barua S, Kashyap SK, Maherchandani S, Kumar N; Role of MAPK/MNK1 signaling in virus replication. *Virus research* **2018**, 253, 48-61, .
102. Pleschka S; RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade. *Biological Chemistry* **2008**, 389(10), 1273-1282, .
103. Huang C, Feng F, Shi Y, Li W, Wang Z, Zhu Y, Yuan S, Hu D, Dai J, Jiang Q; Protein Kinase C Inhibitors Reduce SARS-CoV-2 Replication in Cultured Cells. *Microbiology spectrum* **2022**, 10(5), e01056-01022, .
104. Liu M, Yang Y, Gu C, Yue Y, Wu KK, Wu J, Zhu Y; Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways. *The FASEB Journal* **2007**, 21(7), 1586-1596, .

105. Wieczninska J, Kleniewska P, Pawliczak R;; Oxidative stress-related mechanisms in SARS-CoV-2 infections. *Oxidative Medicine and Cellular Longevity* **2022**, 2022, 5589089, .
106. Suhail S, Zajac J, Fossum C, Lowater H, McCracken C, Severson N, Laatsch B, Narkiewicz-Jodko A, Johnson B, Liebau J;; Role of oxidative stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) infection: a review. *The protein journal* **2020**, 39(6), 644-656, .
107. Berlansky S, Sallinger M, Grabmayr H, Humer C, Bernhard A, Fahrner M, Frischauf I;; Calcium signals during SARS-CoV-2 infection: assessing the potential of emerging therapies. *Cells* **2022**, 11(2):253 **2022**, 11(2), 253, .
108. Vollbracht C, Kraft K;; Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C. *Frontiers in Pharmacology* **2022**, 13, 899198, .
109. Aiello E, Cingolani H;; Angiotensin II stimulates cardiac L-type Ca<sup>2+</sup> current by a Ca<sup>2+</sup>-and protein kinase C-dependent mechanism. *American Journal of Physiology-Heart and Circulatory Physiology* **2001**, 280(4), H1528-H1536, .
110. Verma K, Pant M, Paliwal S, Dwivedi J, Sharma S;; An Insight on Multicentric Signaling of Angiotensin II in Cardiovascular system: A Recent Update. *Frontiers in Pharmacology* **2021**, 12, 734917, .
111. Palacios Y, Ruiz A, Ramon-Luing LA, Ocaña-Guzman R, Barreto-Rodriguez O, Sanchez-Moncivais A, Tecuatzi-Cadena B, Regalado-García AG, Pineda-Gudiño RD, García-Martínez A;; Severe COVID-19 patients show an increase in soluble TNFR1 and ADAM17, with a relationship to mortality. *International journal of molecular sciences* **2021**, 22(16), 8423, .
112. Vieira C, Nery L, Martins L, Jabour L, Dias R, Simões e Silva AC;; Downregulation of membrane-bound angiotensin converting enzyme 2 (ACE2) receptor has a pivotal role in COVID-19 immunopathology. *Current Drug Targets* **2021**, 22(3), 254-281, .
113. Ramos SG, da Cruz Rattis BA, Ottaviani G, Celes MRN, Dias EP;; ACE2 down-regulation may act as a transient molecular disease causing RAAS dysregulation and tissue damage in the microcirculatory environment among COVID-19 patients. *The American journal of pathology* **2021**, 191(7), 1154-1164, .
114. Yalcin HC, Sukumaran V, Al-Ruweidi MKA, Shurbaji S;; Do changes in ace-2 expression affect SARS-CoV-2 virulence and related complications: A closer look into membrane-bound and soluble forms. *International Journal of Molecular Sciences* **2021**, 22(13), 6703, .
115. Tseng YH, Yang RC, Lu TS;; Two hits to the renin-angiotensin system may play a key role in severe COVID-19. *The Kaohsiung Journal of Medical Sciences* **2020**, 36(6), 389-392, .
116. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S;; TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. *Journal of virology* **2014**, 88(2), 1293-1307, .
117. Zipeto D, Palmeira JdF, Argañaraz GA, Argañaraz ER;; ACE2/ADAM17/TMPRSS2 interplay may be the main risk factor for COVID-19. *Frontiers in immunology* **2020**, 11, 2642, .
118. Tang Q, Wang Y, Ou L, Li J, Zheng K, Zhan H, Gu J, Zhou G, Xie S, Zhang J;; Downregulation of ACE2 expression by SARS-CoV-2 worsens the prognosis of KIRC and KIRP patients via metabolism and immunoregulation. *International journal of biological sciences* **2021**, 17(8), 1925, .
119. Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD;; Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *The Journal of pathology* **2020**, 251(3), 228-248, .
120. Haga S, Nagata N, Okamura T, Yamamoto N, Sata T, Yamamoto N, Sasazuki T, Ishizaka Y;; TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. *Antiviral research* **2010**, 85(3), 551-555, .
121. Harte JV, Wakerlin SL, Lindsay AJ, McCarthy JV, Coleman-Vaughan C;; Metalloprotease-Dependent S2'-Activation Promotes Cell-Cell Fusion and Syncytiation of SARS-CoV-2. *Viruses* **2022**, 14(10), 2094, .
122. Kornilov SA, Lucas I, Jade K, Dai CL, Lovejoy JC, Magis AT;; Plasma levels of soluble ACE2 are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19. *Critical care* **2020**, 24(1), 1-3, .
123. Mariappan V, Ranganadin P, Shanmugam L, Rao S, Pillai AB;; Early shedding of membrane-bounded ACE2 could be an indicator for disease severity in SARS-CoV-2. *Biochimie* **2022**, 201, 139-147, .
124. Jia HP, Look DC, Tan P, Shi L, Hickey M, Gakhar L, Chappell MC, Wohlford-Lenane C, McCray Jr PB;; Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. *American Journal of Physiology-Lung Cellular and Molecular Physiology* **2009**, 297(1), L84-L96, .

125. Wang J, Zhao H, An Y; ACE2 Shedding and the Role in COVID-19. *Frontiers in Cellular and Infection Microbiology* **2021**, *11*, 789180, .
126. Rodriguez-Perez AI, Labandeira CM, Pedrosa MA, Valenzuela R, Suarez-Quintanilla JA, Cortes-Ayaso M, Mayán-Conesa P, Labandeira-Garcia JL; Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. *Journal of Autoimmunity* **2021**, *122*, 102683, .
127. Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, Liu J, Harville TO; Development of ACE2 autoantibodies after SARS-CoV-2 infection. *PloS one* **2021**, *16*(9), e0257016., .

---

Retrieved from <https://encyclopedia.pub/entry/history/show/100307>